Max Healthcare Institute Yönetim

Yönetim kriter kontrolleri 2/4

Max Healthcare Institute CEO'su Abhay Soi, Jun2020 tarihinde atandı, in görev süresi 4.42 yıldır. in toplam yıllık tazminatı ₹ 247.33M olup, şirket hissesi ve opsiyonları dahil olmak üzere 79.7% maaş ve 20.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 23.74% ine doğrudan sahiptir ve bu hisseler ₹ 230.73B değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.1 yıl ve 3.5 yıldır.

Anahtar bilgiler

Abhay Soi

İcra Kurulu Başkanı

₹247.3m

Toplam tazminat

CEO maaş yüzdesi	79.7%
CEO görev süresi	4.4yrs
CEO sahipliği	23.7%
Yönetim ortalama görev süresi	5.1yrs
Yönetim Kurulu ortalama görev süresi	3.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Abhay Soi'un ücretlendirmesi Max Healthcare Institute'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	₹11b
Jun 30 2024	n/a	n/a	₹11b
Mar 31 2024	₹247m	₹197m	₹11b
Dec 31 2023	n/a	n/a	₹11b
Sep 30 2023	n/a	n/a	₹10b
Jun 30 2023	n/a	n/a	₹12b
Mar 31 2023	₹140m	₹140m	₹11b
Dec 31 2022	n/a	n/a	₹10b
Sep 30 2022	n/a	n/a	₹9b
Jun 30 2022	n/a	n/a	₹6b
Mar 31 2022	₹140m	₹49m	₹6b
Dec 31 2021	n/a	n/a	₹6b
Sep 30 2021	n/a	n/a	₹5b
Jun 30 2021	n/a	n/a	₹3b
Mar 31 2021	₹117m	₹91m	-₹1b

Tazminat ve Piyasa: Abhay 'nin toplam tazminatı ($USD 2.93M ), Indian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.10M ).

Tazminat ve Kazançlar: Abhay 'in maaşı son bir yılda %20'den fazla arttı.

CEO

Abhay Soi (51 yo)

4.4yrs

Görev süresi

₹247,330,308

Tazminat

Mr. Abhay Soi is a Co-Founder of Halcyon Group. He served as Executive Officer at Ernst & Young LLP. Mr. Soi served as Head of Financial Restructuring group at Ernst & Young and Arthur Anderson.He has in-...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Abhay Soi	Chairman & MD	4.4yrs	₹247.33m	23.74% ₹ 230.7b
Yogesh Sareen	Senior Director & CFO	12.8yrs	₹45.10m	0.0062% ₹ 60.0m
Dhiraj Aroraa	Senior VP	1.8yrs	₹10.00m	Veri yok
Mradul Kaushik	Member of Group Medical Advisory Council	no data	Veri yok	Veri yok
Prashant Singh	Director of Information Technology & Chief Information Officer	5.2yrs	Veri yok	Veri yok
Gagan Palta	General Counsel & Director	less than a year	Veri yok	Veri yok
Anas Wajid	Senior Director and Chief Sales & Marketing Officer	no data	Veri yok	Veri yok
Umesh Gupta	Member of Group Medical Advisory Council	5.3yrs	Veri yok	Veri yok
Sandeep Budhiraja	Member of Group Medical Advisory Council & Group Medical Director	no data	Veri yok	Veri yok
Sanjiv K. Marya	Member of Group Medical Advisory Council	5.1yrs	Veri yok	Veri yok
Anurag Krishna	Chairman of Paediatrics & Paediatric Surgery	3.8yrs	Veri yok	Veri yok
Harinder Chehal	Senior Director & COO - Cluster 2	5.3yrs	Veri yok	Veri yok

5.1yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: 543220 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Abhay Soi	Chairman & MD	5.4yrs	₹247.33m	23.74% ₹ 230.7b
Mradul Kaushik	Member of Group Medical Advisory Council	no data	Veri yok	Veri yok
Gagan Palta	General Counsel & Director	less than a year	Veri yok	Veri yok
Umesh Gupta	Member of Group Medical Advisory Council	no data	Veri yok	Veri yok
Sandeep Budhiraja	Member of Group Medical Advisory Council & Group Medical Director	no data	Veri yok	Veri yok
Sanjiv K. Marya	Member of Group Medical Advisory Council	no data	Veri yok	Veri yok
N. Venkatesan	Director & Chief Procurement Officer	no data	Veri yok	Veri yok
Mahendra Lodha	Non-Executive Independent Director	5.4yrs	₹5.25m	Veri yok
Narayan Seshadri	Non-Executive Non-Independent Director	1.5yrs	₹3.83m	Veri yok
Pradeep Chowbey	Member of Group Medical Advisory Council	no data	₹4.42m	Veri yok
Harit Chaturvedi	Member of Group Medical Advisory Council	no data	Veri yok	Veri yok
Dinesh Khullar	Member of Group Medical Advisory Council	no data	Veri yok	Veri yok

3.5yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 543220 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.5 yıldır).

Max Healthcare Institute Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Max Healthcare Institute Limited Cessation of Gautam Wadhwa as Director

Max Healthcare Institute Limited Appoints Kummamuri Narasimha Murthy as an Independent Director

Insufficient new directors

Max Healthcare Institute Limited, Annual General Meeting, Sep 20, 2024

Max Healthcare Institute Limited Announces Change in Management

Max Healthcare Institute Limited, Annual General Meeting, Sep 27, 2023

Recent updates

Consensus revenue estimates increase by 13%

Max Healthcare Institute Limited (BSE:543220) acquired remaining 36.35% stake in Jaypee Healthcare Limited from Lakshdeep Investments & Finance Pvt. Ltd and Lakshdeep Infrastructure and Holding Private Limited for INR 2.3 billion.

Price target increased by 8.2% to ₹1,017

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

Max Healthcare Institute Limited Cessation of Gautam Wadhwa as Director

Max Healthcare Institute Limited (BSE:543220) completed the acquisition of 63.65% stake in Jaypee Healthcare Limited from Lakshdeep Investments & Finance Pvt. Ltd and Lakshdeep Infrastructure and Holding Private Limited for INR 4 billion.

Max Healthcare Institute Limited Appoints Kummamuri Narasimha Murthy as an Independent Director

Max Healthcare Institute Limited Announces Declaration of Final Dividend

Max Healthcare Institute Limited (BSE:543220) entered into a Strategic Collaboration Agreement to acquire 64% stake in Jaypee Healthcare Limited from Lakshdeep Investments & Finance Pvt. Ltd and Lakshdeep Infrastructure and Holding Private Limited for an enterprise value of INR 16.6 billion.

Insufficient new directors

Max Healthcare Institute Limited to Report Q2, 2025 Results on Nov 06, 2024

Upcoming dividend of ₹1.50 per share

Max Healthcare Institute Limited, Annual General Meeting, Sep 20, 2024

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Max Healthcare Institute Limited to Report Q1, 2025 Results on Aug 01, 2024

Max Healthcare Institute Limited Recommends Final Dividend for the Financial Year 2023-24

Full year 2024 earnings: EPS and revenues miss analyst expectations

Max Healthcare Institute Limited to Report Q4, 2024 Results on May 22, 2024

Max Healthcare Institute Limited (BSE:543220) agreed to acquire Alexis Multi-speciality Hospital Private Limited for approximately INR 3720 million.

Price target increased by 11% to ₹767

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Max Healthcare Institute Limited to Report Nine Months, 2024 Results on Jan 31, 2024

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Max Healthcare Institute Limited to Report Q2, 2024 Results on Nov 06, 2023

Max Healthcare Institute Limited Approves the Declaration of Final Dividend for the Financial Year Ended March 31, 2023

Max Healthcare Institute Limited Announces Change in Management

Max Healthcare Institute Limited Provides Update on Petition Filed by the Company Against Touch Healthcare Private Limited and Others

Max Healthcare Institute Limited, Annual General Meeting, Sep 27, 2023

Max Healthcare Institute Limited Announces Appointment of Amrita Gangotra as Additional Director (Non-Executive and Independent Woman Director)

Price target increased by 7.1% to ₹611

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Max Healthcare Institute Limited to Report Q1, 2024 Results on Aug 07, 2023

Aster Eye $300 million India Stake Sale

Price target increased by 8.1% to ₹564

Full year 2023 earnings: EPS and revenues miss analyst expectations

Max Healthcare Institute Limited to Report Q4, 2023 Results on May 16, 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates increase by 12%

Max Healthcare Institute Limited Announces Executive Changes

Max Healthcare Institute Limited to Report Q3, 2023 Results on Feb 02, 2023

Blackstone, CVC Manipal, Max Reportedly Eye KIMS Stake

Max Healthcare Reportedly Eyeing AMRI Hospitals

Price target increased to ₹512

Price target increased to ₹498

KKR, Temasek Reportedly Vie for Care Hospitals; Deal Likely at $1 Billion

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Max Healthcare Institute Limited Announces Management Changes

Max Healthcare Institute Limited to Report Q2, 2023 Results on Nov 01, 2022

Max Healthcare Institute Limited Announces Resignation of Ruchi Mahajan as Company Secretary and Compliance Officer

Max Healthcare Institute Limited Announces Cessation of Prashant Kumar as Non-Executive Non-Independent Director

Investor sentiment improved over the past week

Max Healthcare Institute Limited Announces Resignation of Gaurav Trehan as Non-Executive Non-Independent Director

KKR Reportedly Plans to Exit Max Healthcare by Selling its Entire 27.54% Stake

Max Healthcare Institute Limited, Annual General Meeting, Sep 26, 2022

High number of new directors

Max Healthcare Institute Limited to Report Q1, 2023 Results on Aug 10, 2022

KKR Affiliate Not in Talks for Stake Sale in Max Health

KKR Reportedly May Sell Stake in Max

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ontario Teachers' Pension Plan Board, Max Healthcare Reportedly Lead the Race for Sahyadri Hospitals

Ontario Teachers' Pension Plan Board, Max Healthcare Reportedly Lead the Race for Sahyadri Hospitals

Max Healthcare Institute Limited to Report Q4, 2022 Results on May 25, 2022

High number of new and inexperienced directors

High number of new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Max Healthcare Institute Limited Announces Executive Changes

Max Healthcare Institute Limited to Report Q3, 2022 Results on Feb 12, 2022

Consensus forecasts updated

Price target increased to ₹444